Silva Pharmaceuticals Limited (DSE: SILVAPHL)
Bangladesh
· Delayed Price · Currency is BDT 10.40
0.00 (0.00%)
At close: Nov 14, 2024
Silva Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | 2018 - 2016 |
| Revenue | 611.62 | 716.87 | 778.67 | 799.25 | 763.34 | 732.45 | Upgrade
|
| Revenue Growth (YoY) | -17.94% | -7.94% | -2.57% | 4.70% | 4.22% | 6.89% | Upgrade
|
| Cost of Revenue | 437.92 | 487.58 | 492.89 | 486.26 | 465.91 | 441.53 | Upgrade
|
| Gross Profit | 173.7 | 229.29 | 285.78 | 312.99 | 297.42 | 290.92 | Upgrade
|
| Selling, General & Admin | 199.75 | 185.61 | 175.07 | 171.85 | 158.03 | 144.42 | Upgrade
|
| Other Operating Expenses | -1.1 | -1.1 | -1.05 | -0.94 | -0.93 | - | Upgrade
|
| Operating Expenses | 198.65 | 184.51 | 174.02 | 170.91 | 157.1 | 148.08 | Upgrade
|
| Operating Income | -24.95 | 44.78 | 111.76 | 142.09 | 140.32 | 142.84 | Upgrade
|
| Interest Expense | -3.8 | -3.61 | -4.71 | -2.78 | -1.46 | -3.61 | Upgrade
|
| Interest & Investment Income | 5.56 | 9.45 | 9.67 | 12.05 | 20.22 | 17.61 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.31 | -0.26 | -0.05 | -0.02 | - | 0.48 | Upgrade
|
| Pretax Income | -23.5 | 50.36 | 116.67 | 151.35 | 159.09 | 157.32 | Upgrade
|
| Income Tax Expense | 7.42 | 17.29 | 14.41 | 31.49 | 40.14 | 14 | Upgrade
|
| Net Income | -30.91 | 33.08 | 102.26 | 119.85 | 118.94 | 143.32 | Upgrade
|
| Net Income to Common | -30.91 | 33.08 | 102.26 | 119.85 | 118.94 | 143.32 | Upgrade
|
| Net Income Growth | - | -67.65% | -14.68% | 0.77% | -17.01% | 54.12% | Upgrade
|
| Shares Outstanding (Basic) | 137 | 137 | 137 | 137 | 137 | 137 | Upgrade
|
| Shares Outstanding (Diluted) | 137 | 137 | 137 | 137 | 137 | 137 | Upgrade
|
| Shares Change (YoY) | - | - | - | - | - | 30.00% | Upgrade
|
| EPS (Basic) | -0.23 | 0.24 | 0.75 | 0.88 | 0.87 | 1.05 | Upgrade
|
| EPS (Diluted) | -0.23 | 0.24 | 0.75 | 0.88 | 0.87 | 1.05 | Upgrade
|
| EPS Growth | - | -67.65% | -14.68% | 0.93% | -17.14% | 18.55% | Upgrade
|
| Free Cash Flow | 11.7 | -16.7 | -16.8 | 82.22 | -21.14 | -15.33 | Upgrade
|
| Free Cash Flow Per Share | 0.09 | -0.12 | -0.12 | 0.60 | -0.15 | -0.11 | Upgrade
|
| Dividend Per Share | 0.100 | 0.100 | 0.300 | 0.500 | 0.500 | 0.571 | Upgrade
|
| Dividend Growth | -66.67% | -66.67% | -40.00% | 0% | -12.50% | - | Upgrade
|
| Gross Margin | 28.40% | 31.98% | 36.70% | 39.16% | 38.96% | 39.72% | Upgrade
|
| Operating Margin | -4.08% | 6.25% | 14.35% | 17.78% | 18.38% | 19.50% | Upgrade
|
| Profit Margin | -5.05% | 4.61% | 13.13% | 15.00% | 15.58% | 19.57% | Upgrade
|
| Free Cash Flow Margin | 1.91% | -2.33% | -2.16% | 10.29% | -2.77% | -2.09% | Upgrade
|
| EBITDA | 32.26 | 107.29 | 174.33 | 207.38 | 209 | 195.18 | Upgrade
|
| EBITDA Margin | 5.27% | 14.97% | 22.39% | 25.95% | 27.38% | 26.65% | Upgrade
|
| D&A For EBITDA | 57.21 | 62.51 | 62.57 | 65.29 | 68.68 | 52.34 | Upgrade
|
| EBIT | -24.95 | 44.78 | 111.76 | 142.09 | 140.32 | 142.84 | Upgrade
|
| EBIT Margin | -4.08% | 6.25% | 14.35% | 17.78% | 18.38% | 19.50% | Upgrade
|
| Effective Tax Rate | - | 34.33% | 12.35% | 20.81% | 25.23% | 8.90% | Upgrade
|
| Advertising Expenses | - | 3.81 | 5.92 | 20.65 | 21.16 | 20.16 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.